Simulations Plus, Inc. (NASDAQ:SLP) Given Average Rating of “Hold” by Analysts

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned a consensus recommendation of “Hold” from the nine brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $20.90.

Several equities analysts have weighed in on SLP shares. William Blair cut Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. Craig Hallum downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target on the stock. in a report on Thursday. Weiss Ratings raised shares of Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, June 5th. Wall Street Zen downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Finally, TD Cowen reduced their target price on shares of Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a research report on Friday, April 10th.

Simulations Plus Stock Down 0.8%

Shares of SLP stock opened at $18.10 on Tuesday. The company has a market cap of $365.62 million, a price-to-earnings ratio of -5.78 and a beta of 1.32. Simulations Plus has a 52 week low of $11.09 and a 52 week high of $21.01. The firm has a 50 day moving average of $15.44 and a 200-day moving average of $15.58.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.08. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. The business had revenue of $24.29 million during the quarter, compared to the consensus estimate of $21.66 million. Analysts anticipate that Simulations Plus will post 0.85 earnings per share for the current year.

Institutional Trading of Simulations Plus

Large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Simulations Plus by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock valued at $233,000 after purchasing an additional 390 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Simulations Plus by 1.3% during the first quarter. Bank of New York Mellon Corp now owns 63,592 shares of the technology company’s stock valued at $752,000 after purchasing an additional 844 shares during the last quarter. Deutsche Bank AG lifted its holdings in Simulations Plus by 5.9% during the fourth quarter. Deutsche Bank AG now owns 15,825 shares of the technology company’s stock valued at $288,000 after purchasing an additional 875 shares during the last quarter. Prudential Financial Inc. lifted its holdings in Simulations Plus by 5.7% during the second quarter. Prudential Financial Inc. now owns 17,213 shares of the technology company’s stock valued at $300,000 after purchasing an additional 930 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in Simulations Plus by 3.8% during the second quarter. Invesco Ltd. now owns 36,452 shares of the technology company’s stock valued at $636,000 after purchasing an additional 1,323 shares during the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.